Key result
The novel human tropomyosin isoform TPM1κ is upregulated in dilated cardiomyopathy and heart failure, and its overexpression in transgenic mice causes dilated cardiomyopathy with decreased myofilament calcium sensitivity.
Increased levels of the novel tropomyosin isoform TPM1kappa in the heart lead to dilated cardiomyopathy and contractile dysfunction, providing a potential mechanism for the consequences of TM isoform switching in heart failure.
Answers are grounded in this paper and cite their sources.
TPM1kappa detection in human hearts is hypothesis-generating; leaves open its role in contractile regulation or disease.
BACKGROUND: Tropomyosin (TM), an essential actin-binding protein, is central to the control of calcium-regulated striated muscle contraction. Although TPM1alpha (also called alpha-TM) is the predominant TM isoform in human hearts, the precise TM isoform composition remains unclear. METHODS AND RESULTS: In this study, we quantified for the first time the levels of striated muscle TM isoforms in human heart, including a novel isoform called TPM1kappa. By developing a TPM1kappa-specific antibody, we found that the TPM1kappa protein is expressed and incorporated into organized myofibrils in hearts and that its level is increased in human dilated cardiomyopathy and heart failure. To investigate the role of TPM1kappa in sarcomeric function, we generated transgenic mice overexpressing cardiac-specific TPM1kappa. Incorporation of increased levels of TPM1kappa protein in myofilaments leads to dilated cardiomyopathy. Physiological alterations include decreased fractional shortening, systolic and diastolic dysfunction, and decreased myofilament calcium sensitivity with no change in maximum developed tension. Additional biophysical studies demonstrate less structural stability and weaker actin-binding affinity of TPM1kappa compared with TPM1alpha. CONCLUSIONS: This functional analysis of TPM1kappa provides a possible mechanism for the consequences of the TM isoform switch observed in dilated cardiomyopathy and heart failure patients.
No takes yet. Share an insight, caveat, or question.
Rajan et al. (2010) studied Dilated Cardiomyopathy and Heart Failure. TPM1κ overexpression vs. Non-transgenic (Ntg) controls was evaluated on Myofilament calcium sensitivity (pCa50) (p=<0.05). The novel human tropomyosin isoform TPM1κ is upregulated in dilated cardiomyopathy and heart failure, and its overexpression in transgenic mice causes dilated cardiomyopathy with decreased myofilament calcium sensitivity.
Synapse has enriched 10 related papers. Consider them for comparative context: